Efficacy analysis of flunarizine and betahistine in the treatment of patients with peripheral vertigo
氟桂利嗪与倍他司汀治疗周围性眩晕患者的疗效分析

摘要

目的 分析氟桂利嗪与倍他司汀联用方案针对周围性眩晕病症的治疗效果及安全性。方法 筛选本院2025年1月-2025年12月间接诊的80例周围性眩晕病例作为研究样本，依据治疗方案差异分组。对照组40例仅实施倍他司汀单一疗法，观察组40例则在上述基础上增配氟桂利嗪进行协同干预。比对两组的总体治愈效率、眩晕功能障碍指数（Dizziness Handicap Inventory; DHI）分值、不良反应发生率。结果 观察组临床治疗总有效率数值比对照组高（P<0.05）。治疗2周后DHI数值组间比较，观察组低于对照组，差异有统计学意义（P<0.05）。不良反应发生率组间比较差异无统计学意义（P>0.05），所有不适反应程度轻微并能自主消退。结论 采用氟桂利嗪搭配倍他司汀处置周围性眩晕成效稳固，能更优地缓解眩晕表现并优化生存质量，同时具备优良的安全性。

Abstract

Objective To analyze the efficacy and safety of flunarizine combined with betahistine in the treatment of peripheral vertigo.
Methods Eighty patients with peripheral vertigo admitted to our hospital between January, 2025 and December, 2025 were selected as research samples, and grouped according to the difference in treatment regimens. The control group (n = 40) was only treated with betahistine monotherapy, and the observation group (n = 40) was treated with flunarizine on the basis of the above. The overall cure efficiency, Dizziness Handicap Inventory (DHI) score and incidence of adverse reactions were compared between the two groups.
Results The total effective rate of clinical treatment in the observation group was higher than that in the control group (P<0.05). After 2 weeks of treatment, the DHI value of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). All adverse reactions were mild and resolved spontaneously.
Conclusion   Flunarizine combined with betahistine is effective in the treatment of peripheral vertigo, which can better alleviate vertigo and optimize the quality of life, and has excellent safety.